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PCongenital Heart Disease
Transcatheter Closure of
Perimembranous Ventricular Septal Defects
Early and Long-Term Results
Gianfranco Butera, MD, PHD, Mario Carminati, MD, Massimo Chessa, MD, PHD,
Luciane Piazza, MD, Angelo Micheletti, MD, Diana Gabriella Negura, MD, Raul Abella, MD,
Alessandro Giamberti, MD, Alessandro Frigiola, MD
San Donato Milanese, Italy
Objectives We sought to analyze safety, efficacy, and follow-up results of percutaneous closure of perimembranous ventric-
ular septal defects (pmVSD).
Background Results of pmVSD transcatheter closure have been reported in the literature; however, follow-up data are still
limited.
Methods Between January 1999 and June 2006, 104 patients underwent percutaneous closure of a pmVSD at our institu-
tion. An Amplatzer VSD device (muscular or eccentric) (AGA Medical Corp., Golden Valley, Minnesota) was used
in all subjects.
Results The mean age at closure was 14 years (range 0.6 to 63 years). The attempt to place a device was successful in
100 patients (96.2%). The median device size used was 8 mm (range 4 to 16 mm). No deaths occurred. Total
occlusion rate was 47% at completion of the procedure, rising to 84% at discharge and 99% during the follow-up. A
total of 13 early complications occurred (11.5%), but in all but 2 subjects (1.9%) these were transient. The me-
dian follow-up was 38.5 months. The most significant complication was complete atrioventricular block (cAVB),
which required pacemaker implantation in 6 subjects (5.7%; 2 in the early phase and 4 during the follow-up).
Cox proportional hazards regression analysis showed that the only variable significantly associated with the oc-
currence of this complication was age at the time of the procedure (p  0.028; relative risk 0.25). All subjects
experiencing this problem were 6 years old.
Conclusions In the current era and in experienced hands, pmVSD closure can be performed safely and successfully. The ma-
jor concern is the occurrence of cAVB; therefore, very careful monitoring of rhythm is mandatory during
follow-up. (J Am Coll Cardiol 2007;50:1189–95) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.03.068e
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(urgical closure of a perimembranous ventricular septal
efect (pmVSD) is now a routine procedure. It has minimal
ortality, although it is still associated with the potential
isks of complete atrioventricular block (cAVB), postperi-
ardiotomy syndrome, wound infection, neurologic sequelae
fter cardiopulmonary bypass, and chylothorax (1–6).
In the last decade, percutaneous techniques to close
ardiac defects have been developed. Closure of atrial septal
efects, patent ductus arteriosus, and muscular ventricular
eptal defects using transcatheter devices has been widely
eported (6–14). More recently, percutaneous techniques
nd devices have been developed specifically for the closure
f pmVSD. The initial experience in humans appears
rom the Department of Pediatric Cardiology and GUCH Unit, Policlinico San
onato, Instituto Ricerca e Cura a Carattere Scientifico, San Donato Milanese, Italyp
Manuscript received September 22, 2006; revised manuscript received February 15,
007, accepted March 21, 2007.ncouraging (15,16), but there are no data from large series
f patients with an adequate follow-up.
Here, we report our early and mid-term follow-up results
f percutaneous closure of pmVSD in 104 subjects.
ethods
etween January 1999 and June 2006, we prospectively
ollected data on 104 patients who underwent transcatheter
losure of a pmVSD at our institution. The patients’ general
haracteristics are reported in Table 1. Patients were as-
essed by a standard echocardiographic protocol: all patients
nderwent transthoracic echocardiography (TTE) that was
erformed with a Vingmed 800 (Vingmed Sound, Horten,
orway) and a System Five performance ultrasound system
Vingmed Sound) using a transducer appropriate to each
atient’s size and body weight.
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Perimembranous VSD Percutaneous Closure September 18, 2007:1189–95Inclusion and exclusion criteria.
The criteria for inclusion in this
study were clinical and/or echo-
cardiographic evidence of a signif-
icant left-to-right shunt through a
pmVSD.
A left-to-right shunt was con-
sidered to be significant when
the following were found: 1) car-
diomegaly on chest X-ray; 2) left
atrial enlargement, defined as a
left atrial to aortic ratio 1.5; 3)
left ventricular enlargement (left
ventricular volume overload), de-
fined as a left ventricular end-
diastolic diameter 2 standard
deviations (SD) above the mean
for the patient’s age; and 4)
ymptoms including frequent respiratory infections and/or
ailure to thrive and New York Heart Association functional
lass II or greater. Frequent respiratory infections were
efined as more than 6 events/year (17). Failure to thrive
as defined according to Hamil et al. (18).
We intended that patients should weigh at least 6 kg to
e eligible for percutaneous closure of a pmVSD. However,
he ideal weight for percutaneous treatment was considered
o be above 8 to 10 kg.
Only subjects with a rim of at least 1 mm separating the
ortic valve from the pmVSD were included. We excluded
atients with an infundibular defect, patients with pmVSD
nd prolapse of an aortic cusp, and patients with pmVSD
nd malalignment.
Patients or parents of the children gave their informed
ritten consent to the procedure.
evices and delivery systems used. Two different Am-
latzer devices (AGA Medical Corp., Golden Valley, Min-
esota) were used: the muscular ventricular septal defect
ccluder (MVSD-O) and the perimembranous ventricular
eptal defect occluder (PMVSD-O) (14–17). These devices
ave a woven mesh of 72 nitinol wires with shape memory.
hey are made of a 0.004- to 0.005-inch nitinol wire with
polyester mesh inside. These devices and their delivery
ystems have been previously described (14). We used the
uscular VSD device in our early experience before the
Abbreviations
and Acronyms
cAVB  complete
atrioventricular block
MVSD-O  muscular
ventricular septal defect
occluder
pmVSD  perimembranous
ventricular septal defect
PMVSD-O 
perimembranous
ventricular septal defect
occluder
TEE  transesophageal
echocardiography
TTE  transthoracic
echocardiography
eneral Characteristics
Table 1 General Characteristics
n 104
Gender (F/M) 58/46
Age (yrs) Median 14 (range 0.6 to 63)
Age groups
10 yrs 66 patients
10–20 yrs 15 patients
20 yrs 23 patientsm
Weight (kg) Median 26.5 (range 6.5 to 96)embranous device was available and when a “subaortic
im” of at least 5 mm was present. Finally, we used the
uscular VSD device in some cases with an associated
neurysm of the ventricular septum.
rocedure. Percutaneous closure of a VSD was performed
nder general anesthesia with orotracheal intubation. Pa-
ients were given 100 IU/kg heparin and antibiotics intra-
enously. The procedure was performed under fluoroscopic
nd transesophageal echocardiographic (TEE) control. Ac-
ess was through the right femoral vein and left femoral
rtery.
Standard right and left cardiac catheterization, standard
eft ventriculography, and angiography of the ascending
orta were performed in all cases. The size of the VSD and
ts relation to the aorta were confirmed. The diameter of the
SD was measured on the left ventricular side and was
alculated by integrating data from TEE and angiographic
easurements. A device 1 to 2 mm larger than the mea-
ured VSD diameter was chosen.
The VSD was crossed from the left ventricle using a right
oronary artery catheter (Cordis Corp., Miami, Florida) or
n Amplatzer right coronary catheter (Cordis Corp.) and an
xchange floppy Terumo guidewire (Terumo Europe, Leu-
en, Belgium) was advanced into the pulmonary artery or
he superior or inferior vena cava. The wire was then snared
EV3, Plymouth, Minnesota) to establish an arteriovenous
ircuit.
Technical details regarding closure procedures for pmVSD
ave been previously reported in detail (14).
Early in our experience, we closed some cases of pmVSD
ith a 5 mm rim toward the aortic valve using a
etrograde aortic approach and an MVSD-O. In those
ases, the VSD was crossed from the left ventricle and the
ire was placed in the apex of the right ventricle. The long
heath was advanced from the aorta, through the VSD into
he right ventricular apex. The device was advanced in the
ong sheath, and then the distal disc was opened in the right
entricle and withdrawn to the septum. The proximal disc
as then opened, taking care to avoid any entrapment of the
ortic valve with the disc of the device. Finally, the correct
osition was confirmed and the device released.
SD analysis. The diameter of the VSD was measured by
TE and TEE using 2-dimensional imaging and color flow
oppler on long- and short-axis views. The vertical diam-
ter was measured during left ventricular angiography using
he views described.
A ventricular septal aneurysm was present in 35 patients
32%). In these cases, VSD size was also measured on the
eft ventricular side. Associated lesions were encountered in
subjects. Multiple defects were treated in 2 patients.
ostsurgical residual VSDs in a perimembranous position
ere treated in 5 subjects.
esidual shunts and valve regurgitation. A residual shunt
as considered to be present when color Doppler flow
apping showed a left-to-right shunt across the interven-
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et width), small (1 to 2 mm color jet width), moderate (2 to
mm color jet width), or large (4 mm color jet width)
19). Valve regurgitation was evaluated by color Doppler
ow imaging in a standard way.
Seven subjects had trivial aortic regurgitation. Seven had
rivial to mild tricuspid regurgitation. Finally, 10 subjects had
rivial to mild mitral regurgitation related to mitral annulus
ilatation due to volume overload of the left ventricle.
ollow-up. All subjects underwent clinical examination,
lectrocardiography, chest X-rays, 24-h electrocardio-
raphic Holter monitoring, and TTE before discharge, at 1,
, and 12 months after the procedure, and yearly thereafter.
efore discharge, urinalysis was performed to exclude he-
olysis. Platelet antiaggregation therapy with 5 mg/kg/day
spirin orally and endocarditis prophylaxis were prescribed
or 6 months.
tatistical methods. Data are expressed as a frequency or
ercentage for nominal variables and as the mean  SD for
ontinuous variables. The Statistix package version 8 (An-
lytical Software, Tallahassee, Florida) was used for the
tatistical computations.
The following dependent outcome variables were ana-
yzed: total complications, cAVB, device embolization, and
ascular complications. The following independent variables
ere included in the analysis: age at procedure, weight at
rocedure, gender, defect type (congenital, residual postsur-
ery), device type (muscular Amplatzer device, eccentric
mplatzer device), device diameter, associated procedures
yes or no), multiple defects (yes or no), ventricular septal
neurysm (yes or no), device diameter/defect diameter
easured on TTE, and device diameter/patient’s weight.
Univariate analysis was performed using the chi-square
est, Fisher exact test, unpaired Student t test, Wilcoxon
ank sum test, 1-way analysis of variance, and the Kruskall-
allis test as appropriate.
Multivariable analysis to study risk factors for the occur-
ence of early complications was performed using multiple
ogistic regression analysis. The regression model diagnostic
as performed by obtaining the standardized residuals and
he Cook’s D and examining them with Wilk-Shapiro and
ankit plot tests. Independent variables with a p value of
0.2 in the univariate analysis were included in the multi-
ariable model. Odds ratios and their 95% confidence
ntervals (CI) were calculated for independent variables
ncluded in the multivariable model (20).
Multivariable analysis using Cox proportional hazard
egression analysis was performed to study the role of
ndependent variables on the occurrence of cAVB in the
arly period and during the follow-up. The proportional
azards assumption was evaluated using the goodness-of-fit
pproach (21).
All tests were 2-sided. A probability value of p  0.05
as considered to be statistically significant. pesults
rocedural data. Data are reported in Table 2. During the
eriod of the study, all subjects with the inclusion criteria
ere sent to the catheterization laboratory with the inten-
ion to treat the defect percutaneously. In 100 of 104
atients the defect was successfully closed (96.2%). In 4
ubjects the procedure was aborted. Technical problems
ccurred in 2 patients (two 8-year-old girls with malaligned
mVSD and prolapse of the aortic cusp): In one girl it was
mpossible to obtain a stable position of the long sheath, and
n the other the device could not be positioned and was
etrieved before unscrewing it. These subjects were treated
ery early in our experience and it is possible that there was
n error in their selection or a lack in operator experience. In
patients (a 5-year-old girl and a 6-year-old boy), cAVB
eveloped during maneuvers of the catheter or Terumo
uidewire. The procedure was stopped in both subjects and
hey both recovered sinus rhythm within 1 to 2 h. They
nderwent uneventful surgical VSD closure.
omplex procedures. Complex procedures (combined
rocedures, multiple pmVSD, postsurgical residual VSD)
ere performed in 12 patients (11.5%). Five subjects
nderwent combined procedures: pulmonary valve dila-
ation in 1 subject, atrial septal defect closure in 1, patent
uctus arteriosus closure in 1, atrial septal defect and
mall patent ductus arteriosus closure in 1, and aortic
oarctation stenting in 1. Two subjects were treated for
ultiple pmVSD within an aneurysm of the ventricular
eptum. Finally, 5 patients underwent percutaneous clo-
ure of a postsurgical residual VSD (pmVSD closure in 4,
esidual post-Fallot in 1). These patients had undergone
urgery a median of 2 years (range 1 to 5 years) before the
ercutaneous procedure.
omplications. EARLY POSTPROCEDURAL COMPLICA-
IONS. No deaths occurred. A total of 13 significant com-
rocedural Data and Devices Used
Table 2 Procedural Data and Devices Used
Fluoroscopic time (min) 29  14 (range 5 to 72)
Procedure time (min) 100  33 (range 45 to 200)
Qp/Qs 2  0.6 (range 1.3 to 5)
Qp/Qs groups
Qp/Qs 2 47 patients
Qp/Qs 2 57 patients
Systolic PA pressure (mm Hg) 27  6
Mean PA pressure (mm Hg) 16  5
VSD diameter on TTE (mm) 7.2  2.4 (range 3 to 16)
Mean size of the device used (mm) 9.2  2.8 (range 4 to 16)
Device diameter/VSD diameter on TTE (%) 131  27 (range 100 to 228)
Type of device used
MVSD-O 14 patients
PMVSD-O 84 patients
Multiple devices 2 patients
VSD-O  muscular ventricular septal defect occluder; PA  pulmonary artery; PMVSD-O,
erimembranous ventricular septal defect occluder; Qp/Qs  pulmonary to systemic flow ratio;
TE  transthoracic echocardiography; VSD  ventricular septal defect.lications occurred in 12 patients (11.5%). These were
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Perimembranous VSD Percutaneous Closure September 18, 2007:1189–95evice embolization (n 2), vascular complications (n 4),
nd rhythm abnormalities (n  7). However, in all but 2
ubjects (1.9%) who needed implantation of a pacemaker,
hese were transient complications and the patients had no
equelae.
Univariate analysis showed that no variable predicted the
ccurrence of early complications. Only 2 variables showed
trend toward significance (device diameter/patient weight:
o complication 0.38  0.27 vs. complication 0.52  0.4;
 0.07). In the multivariable model, device type (p  0.15)
as also included. However, no risk factors were found.
EVICE EMBOLIZATION. This complication occurred in 2
atients (1.9%). In both cases, the device was recaptured—in
he right pulmonary artery in one the descending aorta in the
ther—using a goose-neck snare and a Mullins long sheath. In
hese cases a larger device was chosen and successfully im-
lanted. The occurrence of device embolization was not related
o any of the independent variables studied.
ASCULAR COMPLICATIONS. Femoral arterial thrombosis
ccurred in 3 patients (2.9%). In a 4-year-old girl (18 kg),
ascular surgery of the femoral artery was needed for safe
emoval of a 10-F arterial sheath used to recapture an 8-mm
MVSD-O device that had embolized in the descending
orta. In two 1-year-old girls (7.5 and 7 kg), thrombolysis
ith recombinant tissue plasminogen activator was success-
ul. In addition, a 40-year-old woman developed a femoral
rterovenous fistula needing vascular surgery. The occur-
ence of vascular complications was not related to any of the
ndependent variables studied.
RRHYTHMIC COMPLICATIONS. Significant arrhythmias oc-
urred in 7 patients with a pmVSD (6.7%). Ventricular
brillation requiring external electrical cardioversion occurred
n a 64-year-old woman during maneuvers of the long sheath.
omplete atrioventricular block occurred during the procedure
n 2 subjects in whom the procedure was aborted (already
escribed). Complete atrioventricular block occurred soon after
evice release in 2 subjects with a pmVSD. In 1 child
a 2-year-old boy, 10-mm PMVSD-O) the block was tran-
ient, whereas in the second (a 3.4-year-old girl) it persisted for
ome hours after implantation of a 10-mm PMVSD-O. The
irl was sent for surgery and recovered stable sinus rhythm after
urgical closure and device removal.
Complete atrioventricular block developed 24 h after
mplantation of a 12-mm PMVSD-O in a 2-year-old boy.
permanent pacemaker was implanted into this child who
as recovered stable sinus rhythm during follow-up. A
.4-year-old boy treated with an 8-mm PMVSD-O devel-
ped cAVB 5 days after the procedure. He had a heart rate
f 50 beats/min and was asymptomatic. We decided to treat
im with corticoid therapy (1 mg/kg) for 2 weeks. The
AVB disappeared completely.
Finally, stable cAVB appeared 7 days after procedure in a
-year-old boy who developed vomiting and paleness and pad a heart rate of 40 beats/min. He underwent pacemaker
mplantation.
RANSIENT MINOR COMPLICATIONS. Transient atrial fi-
rillation occurred in a 5-year-old boy; no treatment was
eeded. A transient right bundle branch block occurred in 1
ubject, and a transient left bundle branch block occurred in
other patients. Two subjects developed moderate groin
ematoma. Transient mild hemolysis was recorded in 2
ubjects but resolved spontaneously within 48 h after the
rocedure. Transient left brachial palsy occurred in a 40-
ear-old man.
alve regurgitation and residual shunts. Preoperative
ortic, tricuspid, or mitral valve regurgitation remained
nchanged after the procedure. No significant new regur-
itation of valves occurred. A trivial intraprosthetic residual
hunt was present in 49 subjects (47%) at the end of the
rocedure. At discharge, 17 patients (16%) had a tiny
esidual shunt and none had signs of hemolysis. The TTE
t 1, 6, 12, 24, 36, and 48 months showed a trivial residual
hunt in 1 patient (1%) due to a small fenestration within an
neurysm. There were no significant differences in the
ccurrence of residual shunting between the 2 devices used.
ospital stay. All subjects in whom the percutaneous
rocedure was uneventful stayed in hospital for 2 days after
he procedure. In cases with minor arrhythmic abnormali-
ies, even transient bundle branch blocks, the hospital stay
as prolonged to 72 h. The mean hospital stay was 4  1
ay.
ollow-up. Follow-up data were available for all patients.
he median duration of follow-up was 38.5 months (range
to 72 months). No deaths or cases of endocarditis
ccurred. Patients with failure to thrive had complete
ecovery of growth (from 10th percentile up to 50th
ercentile during follow-up). Subjects with frequent respi-
atory infections had no significant recurrences. Left ven-
ricular dimensions returned to normal in all subjects but
ne (a 7-year-old girl whose left ventricular end-diastolic
iameter was 44 mm). The New York Heart Association
unctional class was I in all subjects.
During the entire follow-up period, 4 subjects developed
AVB. Two out of 4 experienced syncope (a 4-year-old boy
nd a 1.2-year-old girl both treated with an 8-mm
MVSD-O) due to paroxysmal cAVB, 4 and 20 months
fter the procedure, respectively. Another patient (a 2.7-
ear-old boy treated with a 12-mm PMVSD-O) developed
symptomatic cAVB with a heart rate of 40 beats/min 12
onths after closure of the defect. The patient who had the
ransient cAVB successfully treated with corticosteroids
eveloped stable cAVB 8 months after procedure. An
ndocardial ventricular pacemaker was implanted into all of
hese subjects.
nalysis of risk factors for the occurrence of cAVB. A
otal of 9 patients experienced cAVB during the period of
he study. This rhythm abnormality occurred early in 5
atients, whereas in 4 it was a late event. Pacemaker
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AVB; however, in 2 of these subjects the procedure was
borted, the device removed, and the patients sent to
urgery. A pacemaker was implanted in 100% (4 of 4) of the
ases of late cAVB.
Univariate analysis showed that the following variables
ere significantly associated with the occurrence of cAVB:
ge at procedure (no cAVB 14.7  15.6 [95% CI 11.5 to
5.6] years vs. cAVB 2.7 1 [95% CI 1.6 to 3.7] years; p
.0001), weight (no cAVB 36.2  23.3 [95% CI 32 to 41]
g vs. cAVB 15.8  5.7 [95% CI 9.7 to 22] kg; p 
.0001), and device diameter/patient’s weight ratio (no
AVB 0.39  0.29 vs. cAVB 0.66  0.31; p  0.03). The
ccurrence of cAVB was not associated with either the ratio
f the device measure to VSD diameter measured on TTE
no cAVB 135 27% vs. cAVB 121 18%; p 0.9) or the
resence of aneurysm of the ventricular septum (2 of 33 with
neurysm vs. 4 of 65 without aneurysm; p  0.98).
Multivariable analysis using Cox proportional hazard
egression analysis showed that age was significantly asso-
iated with the occurrence of cAVB (p 0.028; relative risk
.25).
iscussion
erimembranous ventricular septal defects are the most
ommon congenital heart defects (1). Subjects with volume
verload of the left chamber due to a VSD require closure of
he defect to prevent ventricular dilatation and dysfunction,
rrhythmias, aortic regurgitation, pulmonary arterial hy-
ertension, endocarditis, or a double-chambered right
entricle (22).
Surgery is the gold standard for pmVSD closure; how-
ver, although it is generally a safe procedure it does have
ome potential risks, including cAVB in 1% to 5% of the
atients (1–4,6), significant residual VSD in 1% to 5%
1–4), the necessity for reoperation in 2% (1,4), and even
eath in 0.5% (1–4). Furthermore, infections, tachyarrhyth-
ias, and neurologic complications may occur (1,4).
Interventional pediatric cardiologists have made efforts in
he last decade to develop a percutaneous approach for the
losure of pmVSD (15,16,23–25). However, only the recent
ntroduction of the Amplatzer muscular and pmVSD oc-
luders has increased the number of subjects in whom
ercutaneous closure is feasible (15,16,26–33).
At the beginning of our experience, we used the
VSD-O in 10 selected patients who had a distance of at
east 5 mm between the superior rim of the defect and the
ortic valve. The device was successfully deployed in all cases
y using a retrograde approach. Similar good results on the
se of muscular VSD devices for properly selected perimem-
ranous defects were reported by Arora et al. (26). When
he PMVSD-O became available, the indications for per-
utaneous closure were expanded also to cases with only 1 to
mm between the defect and the aortic valve (15,16).
tudies in the literature reported that the rate of successful ulosure was between 90% and 100% (15,16,26–33). Con-
istent with this, in our series of 104 patients the rate of
uccessful implantation was 96.2%.
A common morphologic variation is the presence of an
neurysm of the ventricular septum. We found this variant
n 32% of our patients. Usually, we tried to close the true
natomic hole with the most appropriate device, as judged
rom case to case. Sometimes, when the redundant tissue of
he aneurysm was relatively small, the device could cover the
ole and the aneurysm; in cases of very large aneurysms, the
evice was implanted within the aneurysm itself, with
he aim of closing the true anatomic hole and not placing
he device at the “entrance” on the left ventricular side, to
void an oversized device.
A total of 13 significant early complications occurred in
2 patients (11.5%). However, in all but 2 cases (1.9%),
arly complications were transient and the patients had no
equelae. Statistical analysis showed that no variable pre-
icted the occurrence of early complications. The rate of
ajor complications reported in the literature ranges be-
ween 0% and 8.6% (15,16,26–33). No significant valve
egurgitation occurred in our series, and the incidence of
esidual shunting, which was 16% at discharge, decreased to
% during the follow-up. In all cases, the residual shunts
ere graded as trivial.
The only serious concern of percutaneous pmVSD clo-
ure is the occurrence of cAVB. This complication required
acemaker implantation in 6 subjects with pmVSD (5.7%)
n our series. The cAVB rates reported in the literature vary
etween 0% and 5.7% (15,16,26–33). However, it is note-
orthy that most published studies reported only early
ostprocedural results. In our series, the median follow-up
as 38.5 months and cAVB was a late event in 4 out of the
subjects requiring pacemaker implantation. Although
ome authors have emphasized that an oversized device is a
isk factor for the occurrence of cAVB, in particular in
ubjects with pmVSD, this was not confirmed by our data.
ome authors (34,35) have suggested that a course of
teroids should be used in an effort to avoid pacemaker
mplantation. We used this approach successfully in 1
ubject; however, some months later he again developed
table cAVB. Furthermore, although this therapy could be
seful in an acute setting, we believe it is unlikely to be
seful for late events occurring during the follow-up. Mul-
ivariable analysis using Cox proportional hazard regression
nalysis showed that age was significantly associated with
he occurrence of cAVB (p  0.028; relative risk 0.25). It is
otable that cAVB occurred only in subjects who were less
han 6 years old at the time the percutaneous procedure was
erformed. Complete atrioventricular block can occur even
n patients undergoing surgical pmVSD closure; indeed, this
omplication develops in about 1% to 5% of subjects so
reated (1–4,6). However, compared with surgery in which
AVB usually appears early after the operation, in patients
reated percutaneously the occurrence of cAVB is quite
npredictable and it is usually a late problem. This compli-
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o the margins of the pmVSD. Therefore, both surgery and
evice implantation may interfere with atrioventricular con-
uction. Various mechanisms may be involved. The device
ay cause direct compression trauma or provoke an inflam-
atory reaction or scar formation in the conduction tissue.
owever, there are no direct data about the mechanisms
nvolved in the occurrence of cAVB after percutaneous
losure of a pmVSD.
linical implications. The percutaneous approach for the
reatment of congenital heart diseases is appreciated by
atients and their parents because it has less psychologic
mpact (given the absence of a skin scar), the time spent in
ospital is shorter, the procedure causes less pain and
iscomfort, and there is no need for admission to an
ntensive care unit. In the current era, percutaneous pmVSD
losure provides a valuable alternative to surgery. However,
he decision to perform percutaneous closure of pmVSD in
oung subjects must be carefully weighed given the chal-
enging nature of this technique and the risk of cAVB.
ecause of the late occurrence of cAVB, very careful monitor-
ng of rhythm and atrioventricular conduction is mandatory
uring the follow-up. In fact, cAVB may occur in completely
symptomatic subjects. Our rhythm-monitoring protocol after
rocedure included 24-h electrocardiographic Holter re-
ordings at 2 and 6 weeks, 3, 6, 12, 18, and 24 months, and
hen yearly.
tudy limitations. First of all, only in very experienced
ands can these techniques be carried out safely and
omplications managed in the proper way. Furthermore,
ighly specialized surgical back-up must always be available.
econdly, although the techniques of percutaneous pmVSD
losure appear to be safe in the medium-term follow-up, it
s not known whether they are safe in the very long term,
hereas the long-term safety and efficacy of surgery are well
ocumented.
onclusions
ercutaneous pmVSD closure is associated with excellent
uccess and closure rates, no mortality, and low morbidity.
owadays, pmVSD percutaneous closure is a valuable
lternative to surgery. Longer follow-up data and improve-
ents in device characteristics are needed to reduce the risk
f cAVB.
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